Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/28235| Title: | What does endemic COVID-19 mean for the future of rituximab? | Austin Authors: | Liew, David F L ;Robinson, Philip C | Affiliation: | University of Queensland School of Clinical Medicine, Faculty of Medicine, Herston, QLD, Australia Department of Medicine, University of Melbourne, Parkville, VIC, Australia Rheumatology Royal Brisbane & Women's Hospital, Metro North Hospital & Health Service, Herston, QLD, Australia Clinical Pharmacology and Therapeutics |
Issue Date: | 15-Nov-2021 | Date: | 2021-11-15 | Publication information: | The Lancet. Rheumatology 2021; online first: 15 November | URI: | https://ahro.austin.org.au/austinjspui/handle/1/28235 | DOI: | 10.1016/S2665-9913(21)00362-3 | Journal: | The Lancet. Rheumatology | PubMed URL: | 34806035 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.